Results 1 to 10 of about 53,390 (257)
Journal of Advanced Pharmaceutical Technology & Research, 2016 Attention-deficit hyperactivity disorder (ADHD) is a common psychiatric disorder among preschool children but the number of controlled clinical trials regarding psychopharmacological treatment in this age group is limited.
Parvin Safavi +2 more
doaj +2 more sources
Reward‐enhancing effect of methylphenidate is abolished in dopamine transporter knockout mice: A model of attention‐deficit/hyperactivity disorder [PDF]
Neuropsychopharmacology Reports, 2018 Aim Attention‐deficit/hyperactivity disorder is a heterogeneous neurobiological disorder that is characterized by inattention, impulsivity, and an increase in motor activity.
Soichiro Ide +6 more
doaj +2 more sources
Methylphenidate-Induced Menorrhagia in Twin Girls
Iranian Journal of Psychiatry, 2022 Objective: Methylphenidate, a psychostimulant agent, is used in first-line psychopharmacological treatment in children and adolescents with attention-deficit/hyperactivity disorder. Common side effects associated with methylphenidate use in children and
Veysel Özdağ +3 more
doaj +1 more source
The use of methylphenidate for emergence from propofol and ketamine anesthesia in dogs [PDF]
Iranian Journal of Veterinary Medicine, 2018 Background: Methylphenidate (MPH) has been used to induce emergence from general anesthesia. OBJECTIVES: The objective of the present study was to evaluate the effect of MPH on recovery from propofol and ketamine anesthesia in dogs. METHODS: Six healthy
Hadi Imani Rastabi +3 more
doaj +1 more source
Methylphenidate’s Effect on Cerebral Blood Flow in Patients with Narcolepsy [PDF]
Sleep Medicine Research, 2010 We performed 99mTc-ethyl cysteinate dimer brain single-photon emission computed tomography before and after administering methyl-phenidate, for four weeks, to narcolepsy patients with cataplexy.
Eun Yeon Joo +2 more
doaj +1 more source
Should We Continue Methylphenidate Treatment Despite Orofacial or Extremity Dyskinesias?
Psychiatry and Clinical Psychopharmacology, 2021 Attention-deficit/hyperactivity disorder (ADHD) is the most common neuropsychiatric disease affecting 5.3% of school-aged children. Methylphenidate is the primary stimulant, which has been used widely more than 60 years to treat ADHD.
Selcen Yaroglu Kazanci +4 more
doaj +1 more source
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2023 INTRODUCTION Methylphenidate has been shown to improve apathy in patients with Alzheimer's disease (AD). The authors evaluated the impact of methylphenidate on neuropsychiatric symptoms (NPS) of AD, excluding apathy, using data from the Apathy in ...
Emily D. Clark +13 more
doaj +1 more source
Biological Psychiatry Global Open Science, 2022 Background: Methylphenidate is among the most prescribed medications for treating attention-deficit/hyperactivity disorder (ADHD). However, nearly half of pediatric patients with ADHD do not respond to methylphenidate treatment.
Daniel T. Hain +5 more
doaj +1 more source
Severe toxicity due to injected but not oral or nasal abuse of methylphenidate tablets
Swiss Medical Weekly, 2011 BACKGROUND:Non-medical use of methylphenidate is increasing. Little is known about potential acute medical complications associated with recreational use of methylphenidate.
Swiss Medical Weekly
doaj +1 more source
Methylphenidate does not affect convergent and divergent creative processes in healthy adults
NeuroImage, 2020 An increasing number of healthy people use methylphenidate, a psychostimulant that increases dopamine and noradrenaline transmission in the brain, to help them focus over extended periods of time.
Matthijs Baas +4 more
doaj +1 more source